Life Biosciences reports preliminary visual field improvements in two of three glaucoma participants and a threefold ER-100 dose escalation recommendation.
Written By: Mayuresh Salvi, PharmD
Reviewed by: Pharmacally Editorial Team
Life Biosciences has reported initial human data from its Phase 1 trial of ER-100, an investigational therapy being developed for optic neuropathies. In three participants with open-angle glaucoma (OAG), a single intravitreal administration combined with daily oral doxycycline was well tolerated through Day 56, according to the company. Preliminary visual field improvements were observed in two participants, and the Data Safety Monitoring Board (DSMB) recommended dose escalation.
The findings provide an early assessment of ER-100’s tolerability in humans. However, the visual field observations remain preliminary and do not establish clinical efficacy.
Safety Findings Support Dose Escalation
All three participants received ER-100 at Dose Level 1, corresponding to (2 \times 10^{11}) vector genomes (vg). Life Biosciences reported no dose-limiting toxicities (DLTs), serious adverse events (SAEs) or adverse events of special interest (AESIs) through Day 56.
According to the company, reported adverse events were associated with the administration procedure, steroid treatment or pre-existing conditions rather than directly with ER-100. Following the initial safety evaluation, the DSMB recommended escalation to Dose Level 2, or (6 \times 10^{11}) vg, representing a threefold increase over the initial dose.
The recommendation supports continued dose evaluation in the ongoing trial. However, the findings are based on only three participants followed for 56 days and cannot establish the frequency of uncommon or delayed adverse events. The recommended higher dose should also not be interpreted as evidence that its safety has already been demonstrated.
Preliminary Visual Field Changes
Humphrey Visual Field testing showed preliminary improvements in two of the three participants at Day 56. In each participant, at least 28% of tested visual field points showed an improvement of more than 4 decibels (dB), according to Life Biosciences. The company did not report a corresponding improvement for the third participant.
Humphrey Visual Field testing measures a person’s ability to detect light at multiple locations across the visual field. Changes in these measurements can provide information about visual function, but the observations reported in this small study require careful interpretation.
The Phase 1 study is open-label and uncontrolled, making it difficult to determine whether the observed changes resulted from ER-100, measurement variability or other influences. The reported findings do not establish treatment efficacy, and their clinical significance, reproducibility and durability remain uncertain. Further data from additional participants and longer follow-up will be needed to assess whether these observations persist.
Mechanism of ER-100
ER-100 uses an adeno-associated virus (AAV) vector to deliver genetic instructions for three transcription factors: OCT4, SOX2 and KLF4, collectively known as OSK. The investigational therapy is designed to modify cellular gene-expression patterns through controlled expression of these factors; an approach the company calls epigenetic restoration.
Participants receive daily oral doxycycline for eight weeks (56 days) to induce OSK expression. An oral prednisolone taper is also administered to reduce the risk of inflammation associated with the immune response to the viral vector.
The approach targets retinal ganglion cells, which transmit visual information from the retina to the brain. Damage to these cells is a key feature of optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). ER-100 is being investigated for its potential to restore cellular function, but whether this approach can produce clinically meaningful improvements in human vision remains to be established.
Trial Design and Development Milestones
The first-in-human, open-label Phase 1 study (NCT07290244) evaluates the safety and tolerability of a single ER-100 intravitreal injection in adults with OAG and NAION.
The planned enrollment is up to 18 participants, comprising 12 with OAG and six with NAION. At least two dose levels are planned for the OAG cohort. A dose for the NAION cohort will subsequently be selected following consultation between the DSMB and sponsor.
Primary assessments include treatment-emergent adverse events and safety laboratory measures, with evaluations extending through Day 56 and Day 112. The study also evaluates immune responses and visual function. Long-term follow-up is planned through Year 5.
The US Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for ER-100 on January 28, 2026, allowing clinical development to proceed. Life Biosciences announced the first participant dosing on June 9, 2026.
The company describes ER-100 as the first cellular rejuvenation therapy using epigenetic reprogramming to receive FDA clearance to enter human trials. This is a company-reported characterization of the program’s development milestone, not FDA approval of ER-100 for clinical use.
The interim findings mark an early clinical milestone for epigenetic restoration in optic neuropathies. Further safety data, additional participants and longer-term visual assessments will be needed to determine whether the preliminary observations translate into a reproducible and clinically meaningful treatment effect.
References
Life Biosciences. Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies. October 8, 2026.
Evaluating ER-100 for Safety in People with Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions), ClinicalTrials.gov ID NCT07290244
About the Writer
Mayuresh Sunil Salvi (Linkedin) is a PharmD professional and healthcare writer with a strong interest in pharmacovigilance, drug safety, and emerging medical research. He is passionate about exploring new drug discoveries, clinical research, and advances in evidence-based medicine. His interests also include ward rounds, prescription audits, and treatment analysis to support rational pharmacotherapy and improved patient care.